Contents

SUNDAY 6 NOVEMBER
Programme at a glance  2

MONDAY 7 NOVEMBER
Programme at a glance  3
Symposia in detail  7
Parallel sessions in detail  9
Proffered paper sessions in detail  12
Workshops in detail  14

TUESDAY 8 NOVEMBER
Programme at a glance  19
Symposia in detail  23
Parallel sessions in detail  25
Proffered paper sessions in detail  28
Workshops in detail  30

WEDNESDAY 9 NOVEMBER
Programme at a glance  34
Parallel sessions in detail  36
Programme at a glance SUNDAY

Welcome Address
14.20 – 14.30  Introduction from the Chair of the NCRI
Hall 1  Dame Janet Husband, Chair of the National Cancer Research Institute, UK

Prize Awards
14.30 – 14.50  Cancer Research UK Prize ceremony
Hall 1  Presented by Harpal Kumar, Cancer Research UK

Plenary Lecture
Chaired by Sir David Carter, Chair of the Cancer Research UK Prizes Selection Panel
14.50 – 15.30  Cancer Research UK Lifetime Achievement in Cancer Research Prize winner
Hall 1  Aberrant cell signalling in cancer
Chris Marshall, The Institute of Cancer Research, London, UK

Art Exhibition and Refreshment Break
15.30 – 15.40  Beauty and femininity: Life modelling during and after cancer treatment
Hall 1  Harriet Barber
15.40 – 16.30  'Breast Cancer LIFE' by Harriet Barber & 'Saving Faces' by Mark Gilbert
Galleria (Ground level)

Plenary Lectures
Chaired by Owen Sansom, The Beatson Institute for Cancer Research, Glasgow, UK
16.30 – 17.10  Wnt signalling, stem cells and cancer
Hall 1  Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands

17.10 – 17.50  Chemoprevention: Why do we keep getting it wrong?
Hall 1  John Potter, University of Washington, Seattle, USA & Massey University, Wellington, New Zealand

Opening Reception and Trade Exhibition
18.00 – 20.00  For further details, please refer to the Trade Exhibition section in this book
Hall 2

Special Event
20.00 – 21.00  The Bright Club
Room 12
Programme at a glance MONDAY

Breakfast Educational Workshop
08.00 – 08.45  BACR educational workshop
The endothelial cytoskeleton: A dynamic target for cancer therapy
Room 11  Hosted by Chryso Kanthou, Sheffield University, UK

Introduction to the Programme
08.50 – 09.00  Message from the Chair of the 2011 Programme Committee
Hall 1  Nic Jones, Manchester Cancer Research Centre & Cancer Research UK

Plenary Lectures
Chaired by Patrick Johnston, Queen’s University Belfast, UK
09.00 – 09.40  Modelling drug sensitivity and resistance in tumour-derived cell lines
Hall 1  Jeff Settleman, Genentech, California, USA
09.40 – 10.20  Improving cancer survival in England: Driving for the best
Hall 1  Sir Mike Richards, Clinical Director for Cancer and End of Life Care in England, UK

Refreshment Break and Exhibition Viewing
10.20 – 11.00  For further details, please refer to the Trade Exhibition section in this book
Hall 2

Symposia
11.00 - 12.30  Epigenetics and cancer
Room 11  Hosted by Peter D. Adams, Institute of Cancer Sciences, Glasgow, UK
11.00 - 12.30  Predictive mouse models of human cancer
Room 3A  Hosted by David Tuveson, Cancer Research UK Cambridge Research Institute, UK & University of Cambridge, UK
11.00 - 12.30  Stratified medicine
Hall 1  Hosted by Alan Ashworth, The Institute of Cancer Research, London, UK
11.00 - 12.30  Transformational impact of symptom control for cancer patients
Room 3B  Hosted by Peter Selby¹ and Julia Brown², ¹Cancer Research UK Centre, Leeds, UK; ²University of Leeds, UK

Poster Session A and Lunch
12.30 - 14.00  For details of the poster session, please refer to the Poster Abstracts book or CD
Hall 2
Trade Exhibition Viewing

12.30 – 15.30  For further details, please refer to the Trade Exhibition section in this book
Hall 2

Commercial Workshop

13.00 – 14.00  Cancer genomics: Accelerating translational medicine
              Room 12  Hosted by Illumina. Lunch will be provided from 12.40.

Proffered Paper Sessions

14.00 – 15.30  Cancer cell and model systems I
              Room 11  Hosted by Frances Balkwill, Barts Cancer Institute, London, UK

14.00 – 15.30  Diagnosis and therapy
              Room 3A  Hosted by Rosalind Eeles, The Institute of Cancer Research, Sutton, UK

14.00 – 15.30  Cancer awareness, early diagnosis and survivorship
              Room 3B  Hosted by Jane Wardle, University College London, UK

Workshops

14.00 – 15.30  Rethinking the competitive edge of cancer drug development: Optimal translation of cancer treatment from canine to human patients
              Hall 1B  Hosted by Fabien Calvo, French National Cancer Institute, Paris, France

14.00 – 15.30  Patient panel: Sharing experiences and views of clinical research
              Room 4  Hosted by John Wagstaff, Director of Wales Cancer Research Network, UK

14.00 – 15.30  Improving design and analysis of early phase trials in cancer
              Hall 1A  Hosted by Lucinda Billingham, MRC Midland Hub for Trials Methodology Research, Birmingham, UK

Refreshment Break

15.30 – 15.45  Refreshment break

Registration area & Galleria

Parallel Sessions

KEY TO THEMES:

- Diagnosis and therapy
- Epidemiology and prevention
- Information, patients and the public
- Survivorship and end-of-life care
- The cancer cell and model systems
- Tumour-specific research

15.45 – 17.15  Moving towards a molecular rather than a risk-based approach to selecting breast cancer patients who won’t benefit from standard treatment
              Hall 1A  Hosted by David Cameron, University of Edinburgh & NHS Lothian, UK
15.45 – 17.15  **Cell senescence**  
Room 3B  Hosted by Jesus Gil, MRC Clinical Sciences Centre, London, UK

15.45 – 17.15  **Earlier intervention by palliative care: Translating evidence into practice**  
Hall 1C  Hosted by Michael Bennett, University of Leeds, UK

15.45 – 17.15  **Immune control of cancer**  
Room 11  Hosted by Caetano Reis e Sousa, Cancer Research UK London Research Institute, UK

15.45 – 17.15  **Integrating knowledge for the new age: Cancer informatics**  
Hall 1B  Hosted by Bissan Al-Lazikani, The Institute of Cancer Research, Sutton, UK

15.45 – 17.15  **Lifestyle factors in cancer prevention**  
Room 4  Hosted by Laurence Moore, Cardiff University, UK

15.45 – 17.15  **New insights into the biology and management of brain tumours**  
Room 3A  Hosted by Susan Short, University College London, UK

15.45 – 17.15  **Raising awareness of cancer research: The role of education**  
Room 12  Hosted by David Ardron{1} and Frances Balkwill{2}, {1}National Cancer Research Institute Consumer Liaison Group, UK, {2}Barts Cancer Institute, London, UK

---

**Refreshment Break and Exhibition Viewing**

17.15 – 17.45  For further details, please refer to the Trade Exhibition section in this book  
Hall 2

**Clinical Trials Showcase**

Hall 1  Chaired by Matt Seymour, National Cancer Research Network, Leeds, UK

17.45 – 18.05  Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): A phase III randomised trial (ALSYMPCA)  
Christopher Parker, The Royal Marsden NHS Foundation Trust, Sutton, UK

18.05 – 18.25  Comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma: A Phase III randomised, open-label, multicentre trial (BRIM3)  
James Larkin, The Royal Marsden NHS Foundation Trust, London, UK

18.25 – 18.45  Optimal sequencing of adjuvant chemotherapy (CT) and radiotherapy (RT) for women with early breast cancer (EBC): Results of the SECRAB trial. Presented on behalf of the SECRAB Steering Committee  
Indrajit Fernando, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

---

{1} National Cancer Research Institute Consumer Liaison Group, UK  
{2} Barts Cancer Institute, London, UK
18.45 – 19.05 Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukaemia and deletion of TP53: Final results of the National Cancer Research Institute (NCRI) CLL206 Trial

Hall 1 Andrew R. Pettitt, University of Liverpool, UK & Royal Liverpool & Broadgreen University Hospitals NHS Trust, UK

Social Events

19.10 - 21.00 Drinks reception and canapés
Hall 2

20.00 – 22.30 Chair’s reception (by invitation)
Grace Suite, The Hilton Liverpool
Symposia in detail MONDAY

Epigenetics and cancer

Room 11  Hosted by Peter D. Adams, Institute of Cancer Sciences, Glasgow, UK
11.00 – 11.15  Introduction
Peter D. Adams, Institute of Cancer Sciences, Glasgow, UK
11.15 – 11.40  Epigenetic plasticity and the basis of human cancer
Andrew Feinberg, Johns Hopkins University, Baltimore, USA
11.40 – 12.05  Human cancer epigenetics
Manel Esteller, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
12.05 – 12.30  HDAC inhibitors: From bench to clinic, and back again
Nicholas La Thangue, University of Oxford, UK

Predictive mouse models of human cancer

Room 3A  Hosted by David Tuveson, Cancer Research UK Cambridge Research Institute, UK & University of Cambridge, UK
11.00 – 11.15  Introduction
David Tuveson, Cancer Research UK Cambridge Research Institute, UK & University of Cambridge, UK
11.15 – 11.40  Harnessing transposons for cancer gene discovery
Neal Copeland, Institute of Molecular and Cell Biology, Singapore
11.40 – 12.05  Studying therapy response and resistance in mouse models of human breast cancer
Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands
12.05 – 12.30  Development of novel imaging methods in mouse cancer models
Kevin Brindle, Cancer Research UK Cambridge Research Institute & University of Cambridge, UK

Stratified medicine

Hall 1  Hosted by Alan Ashworth, The Institute of Cancer Research, London, UK
11.00 – 11.15  Introduction
Alan Ashworth, The Institute of Cancer Research, London, UK
11.15 – 11.40  Tailoring treatment in lung cancer
Jean Charles Soria, Institute Gustave Roussy, Villejuif, France & University XI, Paris, France
11.40 – 12.05  Parallel clinical trials in cells, mice and patients to define the genetic basis of response and resistance to targeted therapies in CRC
Alberto Bardelli, University of Torino Medical School, Candiolo, Italy
12.05 – 12.30  The challenges for the implementation of molecular diagnostics in the clinical setting
David Gonzalez de Castro, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, Sutton, UK
Transformational impact of symptom control for cancer patients

Room 3B  Hosted by Peter Selby¹ and Julia Brown², ¹Cancer Research UK Centre, Leeds, UK; ²University of Leeds, UK

11.00 – 11.15 Introduction
Peter Selby¹ and Julia Brown², ¹Cancer Research UK Centre, Leeds, UK; ²University of Leeds, UK

11.15 – 11.40 Overview on how symptom control and dealing with toxicity has changed over the last decade and enabled the delivery of more complex and effective treatment
Martin Gore, The Royal Marsden NHS Foundation Trust, London, UK

11.40 – 12.05 Cancer and bone - minimising the clinical impact of bone complications
Robert Coleman, Weston Park Hospital, Sheffield, UK

12.05 – 12.30 Work and cancer survivors
Michael Feuerstein, Uniformed Services University, Bethesda, USA
Parallel sessions in detail MONDAY

KEY TO THEMES:
- Diagnosis and therapy
- Epidemiology and prevention
- Information, patients and the public
- Survivorship and end-of-life care
- The cancer cell and model systems
- Tumour-specific research

Moving towards a molecular rather than a risk-based approach to selecting breast cancer patients who won’t benefit from standard treatment

Hall 1A  Hosted by David Cameron, University of Edinburgh & NHS Lothian, UK
15.45 – 16.00 Introduction
David Cameron, University of Edinburgh & NHS Lothian, UK
16.00 – 16.25 Reducing the burden of breast radiotherapy
John Yarnold, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, Sutton, UK
16.25 – 16.50 Patient and treatment selection in the era of genomic taxonomy of breast cancer
Luca Gianni, San Raffaele Hospital, Milan, Italy
16.50 – 17.15 Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: Visualising the therapeutic effects of metformin in tumour tissue
Michael Lisanti, University of Manchester, UK & Kimmel Cancer Center, Philadelphia, USA

Cell senescence

Room 3B  Hosted by Jesus Gil, MRC Clinical Sciences Centre, London, UK
15.45 – 16.00 Introduction
Jesus Gil, MRC Clinical Sciences Centre, London, UK
16.00 – 16.25 A negative-feedback signalling network controlling OIS
Karen Cichowski, Brigham and Women’s Hospital, Boston, USA
16.25 – 16.50 Oncogene-induced senescence: Not all oncogenes are equal
Peter D. Adams, Institute of Cancer Sciences, Glasgow, UK
16.50 – 17.15 Senescence surveillance in hepatocellular carcinoma
Lars Zender, Helmholtz Centre for Infection Research, Braunschweig, Germany

Earlier intervention by palliative care: Translating evidence into practice

Hall 1C  Hosted by Michael Bennett, University of Leeds, UK
15.45 – 16.00 Introduction
Michael Bennett, University of Leeds, UK
16.00 – 16.25 Evidence supporting palliative care interventions
Michael Bennett, University of Leeds, UK
16.25 – 16.50 Effect of earlier palliative care intervention on patients with advanced lung cancer
Jennifer Temel, Massachusetts General Hospital, Boston, USA
16.50 – 17.15  Short-term palliative care – a new model for the new trajectories in cancer: Development and evaluation
Irene J. Higginson, King’s College London, UK

**Immune control of cancer**

Room 11  Hosted by Caetano Reis e Sousa, Cancer Research UK London Research Institute, UK

15.45 – 16.00  Introduction
Caetano Reis e Sousa, Cancer Research UK London Research Institute, UK

16.00 – 16.25  Lymphoid stress-surveillance – toxins, allergies, and tumour surveillance
Adrian Hayday, Cancer Research UK London Research Institute, UK

16.25 – 16.50  Cancer immunoediting: Immunologic control and shaping of cancer
Robert Schreiber, Washington University School of Medicine, St. Louis, USA

16.50 – 17.15  Intratumoural immune reaction: A novel paradigm for cancer
Jérôme Galon, French National Institute of Health and Medical Research (Inserm), Paris, France

**Integrating knowledge for the new age: Cancer informatics**

Room 18  Hosted by Bissan Al-Lazikani, The Institute of Cancer Research, Sutton, UK

15.45 – 16.00  Introduction
Bissan Al-Lazikani, The Institute of Cancer Research, Sutton, UK

16.00 – 16.25  Chemical biology informatics in compound MOA elucidation
Jeremy Jenkins, Novartis Institutes for BioMedical Research, Inc., Cambridge, USA

16.25 – 16.50  Elucidating clinically relevant gene fusions from transcriptome sequencing data
Christopher Maher, Washington University, St. Louis, USA

16.50 – 17.15  Comparative logical models of signalling networks in normal and transformed hepatocytes
Julio Saez-Rodriguez, European Bioinformatics Institute, Cambridge, UK & EMBL-Genome Biology, Heidelberg, Germany

**Lifestyle factors in cancer prevention**

Room 4  Hosted by Laurence Moore, Cardiff University, UK

15.45 – 16.00  Introduction
Laurence Moore, Cardiff University, UK

16.00 – 16.25  Diet and cancer: Some current controversies
Kay-Tee Khaw, University of Cambridge, UK

16.25 – 16.50  Diet and physical activity for cancer risk reduction – opportunities for endorsing lifestyle change
Annie Anderson, University of Dundee, UK

16.50 – 17.15  TREC-A transdisciplinary approach to obesity and cancer research
Linda Nebeling, National Cancer Institute, Bethesda, USA
New insights into the biology and management of brain tumours

Room 3A  Hosted by Susan Short, University College London, UK
15.45 – 16.00  Introduction
Susan Short, University College London, UK
16.00 – 16.25  Integrated genomic analyses of glioblastoma multiforme: An update from The Cancer Genome Atlas
Roeland Verhaak, MD Anderson Cancer Center, Houston, USA
16.25 – 16.50  Biomarker-driven stratification of medulloblastoma therapy through international clinical trials
Steve Clifford, Newcastle University, Newcastle upon Tyne, UK
16.50 – 17.15  Health-related quality of life in brain tumour patients
Martin J. B. Taphoorn, Medical Centre Haaglanden, The Hague, The Netherlands & VU University Medical Centre, Amsterdam, The Netherlands

Raising awareness of cancer research: The role of education

Room 12  Hosted by David Ardron1 and Frances Balkwill2, 1National Cancer Research Institute Consumer Liaison Group, UK, 2Barts Cancer Institute, London, UK
15.45 – 16.00  Introduction
David Ardron1 and Frances Balkwill2, 1National Cancer Research Institute Consumer Liaison Group, UK, 2Barts Cancer Institute, London, UK
16.00 – 16.25  The ‘Centre of the Cell’ and its role in science education
Frances Balkwill, Barts Cancer Institute, London, UK
16.25 – 16.50  Health research in primary education from the Medicines for Children Research Network
Tina Simpson, Medicines For Children Research Network, UK
16.50 – 17.15  Can we teach it? Yes, we CAM! – A cancer awareness research project at The Thomas Alleyne School, Stevenage
Richard Stephens, The Thomas Alleyne School, Stevenage, UK; NCRI Consumer Liaison Group, UK & Independent Cancer Patients’ Voice, UK
Proffered paper sessions in detail MONDAY

KEY TO THEMES:
- Diagnosis and therapy
- Epidemiology and prevention
- Information, patients and the public
- Survivorship and end-of-life care
- The cancer cell and model systems
- Tumour-specific research

Cancer cell and model systems I

Room 11 Hosted by Frances Balkwill, Barts Cancer Institute, London, UK
14:00 - 14:15 AstraZeneca Prize: Synthetic lethal targeting of DNA double strand break repair deficient cells by human apurinic/apyrimidinic endonuclease (APE1) inhibitors
Rebeka Sultana, University of Nottingham, UK
14:15 – 14:20 Discussion
14:20 - 14:30 Regulation of microRNAs by metabolic stress is essential for aggressive tumour growth in glioblastoma
Sean Lawler, Leeds Institute of Molecular Medicine, UK
14:30 - 14:40 Identification of JAK2/STAT3 as a novel therapeutic target in Kras mutant colorectal cancer
Murugan Kalimutho, Centre for Cancer Research and Cell Biology, Belfast, UK
14:40 - 14:50 Selection for combinational studies through biomarker stratification in colorectal patient-derived explant models
Denis Alferez, AstraZeneca, Oncology Innovative Medicines, Macclesfield, UK & University of Manchester, UK
14:50 - 15:00 Structure of human FANCL
Charlotte Hodson, Cancer Research UK London Research Institute, UK
15:00 - 15:10 Notch signalling mediates myofibroblast differentiation of carcinoma-associated fibroblasts
Ahmet Acar, Paterson Institute for Cancer Research & Breakthrough Breast Cancer Research Unit, Manchester, UK
15:10 - 15:20 Oncogenic signalling downstream of PTEN and PI3K: More than AKT
Nick Leslie, University of Dundee, UK
15:20 - 15:30 Discussion

Diagnosis and therapy

Room 3A Hosted by Rosalind Eeles, Barts Cancer Institute, London, UK
14:00 - 14:15 BACR Translational Research Award: Epigenetic epidemiology: Exploring the epigenome to find biomarkers of cancer risk and prognosis
James M. Flanagan, Breast Cancer Campaign Fellow, Imperial College London, UK
14:15 – 14:25 Seven novel prostate cancer susceptibility loci identified in a multinational consortium, PRACTICAL
Rosalind Eeles, The Institute of Cancer Research, Sutton, UK
14:25 - 14:35 The different genetic alterations between Western and Chinese prostate cancers indicate the aetiology
Xueying Mao, Queen Mary University, London, UK

14:35 - 14:45 Clinicopathological characteristics of HR-deficient epithelial ovarian cancers
Asima Mukhopadhyay, Northern Gynaecological Oncology Center, Gateshead, UK

14:45 - 14:55 Survival update for Vinflunine (Javlor) in second-line transitional cell carcinoma of the urothelium (TCCU)
Jonathan Chambers, Pierre Fabre Ltd, Winchester, UK

14:55 - 15:05 Developing rational drug combination strategies for PARP inhibitors
Farah Rehman, The Breakthrough Breast Cancer Research Centre, London, UK

15:05 – 15:15 Distant disease-free survival is improved amongst symptomatic young onset breast cancer patients found to carry a BRCA1 gene mutation
Diana Eccles, University of Southampton, UK

15:15 - 15:30 Discussion

Cancer awareness, early diagnosis and survivorship

Room 3B Hosted by Jane Wardle, University College London, UK

14:00 - 14:10 Increasing rates of cervical cancer in young women in England: An analysis of national data 1982 – 2006
Robert Alston, University of Manchester, UK

14:10 - 14:20 Diagnostic intervals in breast, colorectal, lung, pancreatic, oesophageal and gastric cancers 2001-2 and 2007-8: Database study
Richard Neal, Cardiff University, UK

14:20 - 14:30 Cancer fatalism: Deterring early presentation and increasing social inequalities?
Jane Wardle, University College London, UK

14:30 - 14:40 Knowledge of lung cancer symptoms and risk factors in Britain – development of a measure and results from a population-based survey
Alice Simon, University College London, UK

14:40 - 14:50 Identification of men with a genetic predisposition to prostate cancer: Targeted screening of BRCA1/2 mutation carriers and controls. The IMPACT study
Elizabeth Bancroft, The Institute of Cancer Research, Sutton, UK

14:50 - 15:00 Lifestyle habits during and after prostatic radiotherapy influences the risk of late toxicity
Robert Thomas, The Primrose Oncology Research Unit & Cranfield University, Bedford, UK

15:00 - 15:10 Fertility preservation in women undergoing treatment for breast cancer in the UK: A questionnaire study
Judy King, Royal Free Hampstead NHS Trust, London, UK

15:10 - 15:20 Factors influencing exercise capacity in people with thoracic cancer
Matthew Maddocks, The University of Nottingham, UK

15:20 - 15:30 Discussion
Breakfast Educational Workshop

08.00 – 08.45 BACR educational workshop
The endothelial cytoskeleton: A dynamic target for cancer therapy

Room 11 Hosted by Chryso Kanthou, Sheffield University, UK

Multiple complex processes associated with the development and maintenance of blood vessel networks require changes in the cytoskeleton of endothelial cells. In tumours, blood vessels are characteristically ‘abnormal’ both in terms of architecture and function, a trait thought to arise at least partly as a consequence of dysregulated cell signalling, leading to defective regulation of the endothelial cytoskeleton. Abnormalities of the tumour vasculature provide unique opportunities for therapeutic intervention. The endothelial cytoskeleton constitutes a dynamic target for many promising vascular-directed therapies currently undergoing testing in the clinic, designed to either halt angiogenesis or disrupt already established tumour blood vessels.

The first part of this workshop will focus on advances in our understanding of the signalling pathways that orchestrate angiogenesis through control of the endothelial cytoskeleton, with emphasis on signalling in tumour angiogenesis. The second part will explore mechanisms through which drugs that target cytoskeletal structures such as microtubules and microfilaments inhibit angiogenesis and disrupt the function of the tumour vasculature.

A better understanding of how angiogenic signals regulate cytoskeletal networks combined with continued efforts into discovering new compounds that target the endothelial cytoskeleton are needed in order to improve current vascular-targeted approaches for the treatment of cancer.

Speakers:
Georgia Mavria, Leeds Institute of Molecular Medicine, University of Leeds, UK
Chryso Kanthou, University of Sheffield, UK

Commercial Workshop

13.00 – 14.00 Cancer genomics: Accelerating translational medicine

Room 12 Hosted by Illumina
Lunch will be provided from 12.40

Join us for latest scientific updates from leading cancer researchers that are applying next-generation sequencing to whole genome and targeted gene studies. Learn how they are accelerating our understanding of cancer genomics, applying the knowledge gained in translational studies, and developing smarter diagnostics. Presentations will highlight the utility of high throughput (HiSeq) and low throughput (MiSeq) systems and applications and demonstrate how these could ultimately transform healthcare.
Afternoon Workshops

14.00 – 15.30 Rethinking the competitive edge of cancer drug development: Optimal translation of cancer treatment from canine to human patients

Hall 1B Hosted by Fabien Calvo, French National Cancer Institute, Paris, France

Over the last 20 years, considerable progress has been made in our understanding of complex tumourigenesis mechanisms both within the cancers cells and with the interaction between the tumours and the surrounding tissues. Mice models have been imperative for our understanding of these processes but are less successful for validating and developing new treatments. This has in many cases been attributed to the disadvantages of fast growing tumors in immuno-compromised animals. New approaches are therefore necessary to complement existing animal models in order to facilitate the transfer of pre-clinical discoveries into clinical progress.

This was recognised in the 2009-2013 French Cancer Control Plan and the support and development of alternative pre-clinical models that better predict the clinical response to new cancer treatments was earmarked as an area of priority.

In recent years comparative oncology studies including genetic, biological and clinical characterisation have revealed a high degree of similarity between spontaneous tumours in dogs and corresponding diseases in humans. Studies have also shown comparable responses to radiotherapy and systemic treatments. Despite a very high degree of genomic identity between different dog breeds, certain breeds are more likely to develop specific types of tumours than others, offering unique opportunities to unravel genetic alterations linked to certain cancers. Dog owners are in general keen to help the development of new treatments that not only can help their pets but ultimately also benefit the treatment of human disease. Taken together, spontaneous tumours in dogs have emerged as an interesting complementary model that can help to bridge the gap between existing murine models and the clinic and allow us to better understand disturbances in the molecular pathways underlying different cancers.

Grouping together resources at an European and international level is now a priority in order to pool skills and resources and to set up joint research programs. Veterinary, clinical and molecular oncologists will form new translational and multidisciplinary consortiums for developing spontaneous dog cancer models. Specific areas of interest will include new treatments, improved imaging, biomarkers and better understanding of the molecular mechanisms underlying certain tumour types. A first multidisciplinary call by the French medical research organization INSERM in collaboration with the French National Cancer Institute INCa on the development of spontaneous tumours in dogs for translational cancer research has been completed.

The scientific community aware of the potential of these issues is still quite small and we now need to spread the gospel to promote interdisciplinary collaborations. The session hosted by the French National Cancer Institute aims to give an up-to-date on comparative oncology and ongoing translational research initiatives in Europe and the US using spontaneous tumours in dogs.

Speakers:

Melissa Paoloni, National Cancer Research Institute, Bethesda, USA

Comparative oncology offers an innovative model for improved drug evaluation. This discipline includes the study of cancer biology, its molecular and genetic markers, and most importantly the assessment of novel therapies in companion animals as a method
to improve treatment and prevent cancers in human patients. Cancer is the leading cause of death in our pet population, and the tumours they develop mirror the complexity of those cancers affecting children and adults. Therefore, clinical trials in pet animals with cancer offer the opportunity to evaluate drugs earlier in their development and define their safety and efficacy, pushing forward agents more likely to benefit human patients and more efficiently weeding failures prior to their initial or continued use in human trials. This is both financially cost effective, by eliminating ineffectual Phase II and III clinical trials, and may spare patients the price of receiving drugs unlikely to improve survival. Both the pharmaceutical and academic research communities have taken notice of the utility of comparative oncology. This is particularly relevant to the field of personalised medicine. The advent of approaches to prescribe individual patient drug regimes is exciting, but it is not known if the current strategies will be adequate to advance outcomes; they require advanced molecular profiling techniques, serial patient tumour biopsies, and a cache of rationally selected drugs available for use. Comparative oncology trials are uniquely capable of evaluating the collection methods, technologies, algorithms and effectiveness of these approaches in a compressed time line, hopefully bringing tailored therapies to human patients more quickly.

Catherine André, Institute of Genetics and Development, CNRS / University of Rennes, France

In humans, genetic analyses of cancers are complex due to their sporadic occurrence, the low incidence of familial forms and genetic polymorphism between patients. Moreover, it is often difficult to obtain samples of tumors and control tissues. In addition, in translational research, some rodent models have reached their limit in the development and test of new therapies, and the opportunity of a naturally occurring cancer model between mice and patients is very welcome!

We propose dog as a spontaneous model to study the genetics of cancers in humans. Indeed, in dog, some cancers, unfrequent in the entire species, segregate with remarkable breed specificity and a high incidence in specific breeds. This is due to the unique history of dogs that have been strongly and continuously artificially selected for several thousand years. Moreover, dogs and humans have important genetic and physiological similarities and share the same environment. The goal of our team is to characterise and propose spontaneous canine cancer models to the medical community, such as melanoma, sarcoma (histiocytic sarcoma and osteosarcoma), lymphoma, etc. To this aim, dog-dedicated genomic tools and the cani-DNA French bio-bank developed by the team will be presented, as well as examples of ongoing cancer projects: (i) Characterisation of the homologies between cancers in dogs and humans, from clinical, histological and molecular viewpoints, (ii) search of predisposing alterations and tumour progression genes as well as somatic alterations. The long-term goal is to improve our knowledge and to identify prognostic markers and therapeutic targets to be translated to humans for the development of new genetic and preclinical models, as indicated in the French Cancer Plan objectives.

David Cameron, Edinburgh Cancer Research Centre, UK
14.00 – 15.30  
**Patient panel: Sharing experiences and views of clinical research**

*Hosted by John Wagstaff*, Director of Wales Cancer Research Network, UK

In this workshop patients who have taken part in research studies are being given the opportunity to contribute to the conference.

The workshop will be introduced by John Wagstaff. Dave Ardron, chair of the NCRI Consumer Liaison Group, will set the context and what has been achieved to date in ensuring the patient voice informs good practice in research.

With the support of clinical research professionals, we will then give a platform to people who have recently participated in clinical trials to share their experiences. Groups will explore and identify how personal experience of participating in trials can improve and inform research practice.

Key points of discussion will be fed back to the whole group with an opportunity for further comments from the floor.

There will be audio and video recording.

14.00 – 15.30  
**Improving design and analysis of early phase trials in cancer**

*Hosted by Lucinda Billingham*, MRC Midland Hub for Trials Methodology Research, Birmingham, UK

The MRC Network of Hubs for Trials Methodology Research (HTMR Network) has been formed to improve the design, conduct, analysis, interpretation, and reporting of clinical trials. The HTMR Network consists of eight regional “Hubs” with expertise in trials methodology. We are pleased to present some of our methodological work in early phase trials in cancer and are delighted to welcome John O’Quigley, pioneer of the continual reassessment method.

Phase I trials typically assess a new treatment for the first time in man and aim to find the optimal dose to take through to further trials and potentially clinical practice. Commonly-used designs for these trials are algorithmic approaches in which each dose escalation decision is based on data from a small group of patients (often 3 per group). An alternative to this design, the continual reassessment method (CRM; O’Quigley et al., 1990), is a model-based approach which enables the optimal dose to be found by cumulatively learning from each patient that participates in the trial. Such early phase trials are increasingly becoming more complex, with dose-finding sometimes involving combinations of agents or being based on toxicity and efficacy outcomes, or needing an efficient design that rolls seamlessly into a phase II trial. Model-based approaches may be more able to encompass such complexities. The workshop will describe, compare and contrast the different approaches and provide opportunity to discuss the advantages and disadvantages of the methods.

**Introduction**  
*Adrian Mander*, MRC Biostatistics Unit Hub for Trial Methodology Research, UK

**Principles of dose-finding studies in cancer: a comparison of popular methods**  
*Chris Weir*¹ and *Thomas Jaki*², ¹Edinburgh HTMR, ²Northwest HTMR, UK

**Extending CRM methodology to two-agent phase I trials**  
*Michael Sweeting*, MRC Biostatistics Unit HTMR, UK
Implementation of phase I/IIA trial in pancreatic cancer
Anne Whitehead, North West HTMR, UK

Keynote lecture
John O’Quigley, Université Pierre et Marie Curie, Paris, France

Discussion and debate of pros and cons of each method.
Programme at a glance TUESDAY

Breakfast Educational Workshop

08.10 – 08.55  BACR educational workshop
Unlocking the development and progression of childhood cancers
Room 11  Hosted by Sue Burchill, Leeds Institute of Molecular Medicine, University of Leeds, UK

Plenary Lectures
Chaired by Chris Boshoff, University College London Cancer Institute, UK

09.00 – 09.40  Genome stability: From worms to human disease
Hall 1  Simon Boulton, Cancer Research UK London Research Institute, UK

09.40 – 10.20  TOR signalling and the control of cell growth
Hall 1  Michael N. Hall, Biozentrum, University of Basel, Switzerland

Refreshment Break and Exhibition Viewing

10.20 – 11.00  For further details, please refer to the Trade Exhibition section in this book
Hall 2

Symposia

11.00 - 12.30  Cancer screening and prevention
Hall 1A  Hosted by Robert Steele, University of Dundee, UK

11.00 - 12.30  Epithelial mesenchymal transition
Room 3B  Hosted by Nicholas Hastie, Institute of Genetics and Molecular Medicine, Edinburgh, UK

11.00 - 12.30  Metabolism and cancer
Room 3A  Hosted by Eyal Gottlieb, The Beatson Institute for Cancer Research, Glasgow, UK

11.00 - 12.30  The diagnostic and therapeutic potential of the tumour microenvironment
Room 11  Hosted by Thorsten Hagemann, Barts Cancer Institute, London, UK

Poster Session B and Lunch

12.30 - 14.00  For details of the poster session, please refer to the Poster Abstracts book or CD
Hall 2

Trade Exhibition Viewing

12.30 – 15.30  For further details, please refer to the Trade Exhibition section in this book
Hall 2
Commercial Workshops

13.00 – 14.00  Headlines of international conferences in 2011 – a Roche-sponsored symposium
Room 11  Hosted by Roche  Lunch will be provided from 12.40.

13.00 – 14.00  New frontiers in cancer: Sequencing the complete cancer genome
Room 12  Hosted by Complete Genomics, Inc.  Lunch will be provided from 12.40.

Proffered Paper Sessions

14.00 – 15.30  Cancer cell and model systems II
Room 3B  Hosted by Caroline Dive, Paterson Institute for Cancer Research, Manchester, UK

14.00 – 15.30  Gastrointestinal cancer
Room 3A  Hosted by Philip Quirke, University of Leeds, UK

14.00 – 15.30  Clinical Trials
Hall 1A  Hosted by Johann de Bono, The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research, Sutton, UK

Workshops

14.00 – 15.30  Improving access to samples for research – the role of engagement
Hall 1B  Hosted by Jane Hair¹ and Margaret Wilcox², ¹NHS Glasgow and Greater Clyde Bio-repository, UK; ²Breast Cancer Campaign Tissue Bank & Independent Cancer Patients’ Voice, UK

14.00 – 15.30  Careers in industry
Room 4  Hosted by Altaf Moledina, on behalf of the NCRI Industry Consultation Group

14.00 – 15.30  Spotlight on survivorship: Developing evidence-based support services
Room 12  Hosted by Owen Sharp, Chief Executive, The Prostate Cancer Charity

14.00 – 15.30  Radiotherapy: The quiet revolution
Room 11  Hosted by Tim Maughan, Gray Institute for Radiation Oncology & Biology, Oxford, UK

14.00 – 15.30  Head and neck cancer research workshop
Hall 1C  Hosted by Catharine West¹ and Richard Shaw², ¹University of Manchester, UK; ²University of Liverpool, UK

Refreshment Break

15.30 – 15.45  Refreshment break
Registration area & Galleria

www.ncri.org.uk/ncriconference
Parallel Sessions

KEY TO THEMES:

- Diagnosis and therapy
- Epidemiology and prevention
- Information, patients and the public
- Survivorship and end-of-life care
- The cancer cell and model systems
- Tumour-specific research

15.45 – 17.15 Chernobyl: Fact from fiction – the benefit of 25 years hindsight and integrated research
Room 3B Hosted by Geraldine Thomas, Chernobyl Tissue Bank & Imperial College, London, UK

15.45 – 17.15 Improving patient outcomes in lymphoma
Room 12 Hosted by John Radford, University of Manchester, UK

15.45 – 17.15 Liver and colorectal cancer
Hall 1A Hosted by Tim Maughan, Gray Institute for Radiation Oncology & Biology, Oxford, UK

15.45 – 17.15 Paediatric oncology: Survivorship from childhood cancer
Hall 1B Hosted by Adam Glaser, St James’s Hospital, Leeds, UK

15.45 – 17.15 Phosphoinositol signalling and cancer
Room 11 Hosted by Bart Vanhaesebroeck, Barts Cancer Institute, London, UK

15.45 – 17.15 Prognostication in advanced cancer: How and why?
Hall 1C Hosted by John Ellershaw, University of Liverpool & Marie Curie Palliative Care Institute Liverpool, UK

15.45 – 17.15 The first century of human tumour virology
Room 4 Hosted by Chris Boshoff, University College London Cancer Institute, London, UK

15.45 – 17.15 Translational control and cancer
Room 3A Hosted by Robert White, The Beatson Institute for Cancer Research, Glasgow, UK

Refreshment Break and Exhibition Viewing
17.15 – 17.45 For further details, please refer to the Trade Exhibition section in this book
Hall 2

Plenary Lectures
Chaired by Sir Mike Richards, Clinical Director for Cancer and End of Life Care in England, UK
17.45 – 18.25 Cancer survivorship: Surveying the landscape of cancer survivorship research
Hall 1 Eva Grunfeld, University of Toronto, Canada
18.25 – 19.05  **Cancer care in 2011 is disease based, not discipline based**  
Hall 1  **Murray Brennan**, Memorial Sloan-Kettering Cancer Center, New York, USA

---

**Social Events**

19.30 – 22.00  **Pfizer Excellence in Oncology Awards (by invitation)**  
Grace Suite, The Hilton Liverpool

20.00 onwards  **Conference dinner and party (ticketed event)**  
The Marquee, BT Convention Centre
Symposia in detail TUESDAY

Cancer screening and prevention

Hall 1A Hosted by Robert Steele, University of Dundee, UK

11.00 – 11.15 Introduction
Robert Steele, University of Dundee, UK

11.15 – 11.40 Food, nutrition, physical activity, and cancer prevention: Evidence and recommendations
Martin Wiseman, World Cancer Research Fund International, London, UK & University of Southampton, UK

11.40 – 12.05 Chemoprevention successes and surprises
John Baron, University of North Carolina, Chapel Hill, USA

12.05 – 12.30 Can genetic risk profiling in colorectal cancer guide prevention and screening?
Malcolm Dunlop, University of Edinburgh, UK & MRC Human Genetics Unit, Edinburgh, UK

Epithelial mesenchymal transition

Room 3B Hosted by Nicholas Hastie, Institute of Genetics and Molecular Medicine, Edinburgh, UK

11.00 – 11.15 Introduction
Nicholas Hastie, Institute of Genetics and Molecular Medicine, Edinburgh, UK

11.15 – 11.40 MicroRNAs, EMT and cancer stem cells
Thomas Brabletz, University of Freiburg, Germany

11.40 – 12.05 Modelling and targeting differentiation-state heterogeneity in cancer
Piyush Gupta, Whitehead Institute for Biomedical Research & Massachusetts Institute of Technology, Cambridge, USA

12.05 – 12.30 Intravital imaging of metastasis
Erik Sahai, Cancer Research UK London Research Institute, UK

Metabolism and cancer

Room 3A Hosted by Eyal Gottlieb, The Beatson Institute for Cancer Research, Glasgow, UK

11.00 – 11.15 Introduction
Eyal Gottlieb, The Beatson Institute for Cancer Research, Glasgow, UK

11.15 – 11.40 Metabolic alterations to support cancer cell proliferation
Matthew Vander Heiden, Koch Institute at MIT, Cambridge, USA

11.40 – 12.05 Predicting selective drug targets in cancer through metabolic networks
Tomer Shlomi, Technion-Israel Institute of Technology, Haifa, Israel

12.05 – 12.30 Imaging tumour metabolism using hyperpolarised 13C magnetic resonance spectroscopy
Kevin Brindle, Cancer Research UK Cambridge Research Institute & University of Cambridge, UK
The diagnostic and therapeutic potential of the tumour microenvironment

Room 11  Hosted by Thorsten Hagemann, Barts Cancer Institute, London, UK

11.00 – 11.15  Introduction
Thorsten Hagemann, Barts Cancer Institute, London, UK

11.15 – 11.40  Modelling the role of the tumour microenvironment in therapeutic response
Michael T. Hemann, Massachusetts Institute of Technology, Cambridge, USA

11.40 – 12.05  The immune suppressive tumour stromal cell expressing Fibroblast Activation Protein (FAP) belongs to a cellular lineage mediating essential physiological functions
Douglas Fearon, Cancer Research UK Cambridge Research Institute, UK & University of Cambridge, UK

12.05 – 12.30  Post-translational chemokine modification prevents intratumoral infiltration of antigen-specific T cells
Vincenzo Bronte, Verona University, Italy
Parallel sessions in detail **TUESDAY**

**KEY TO THEMES:**
- Diagnosis and therapy
- Epidemiology and prevention
- Information, patients and the public
- Survivorship and end-of-life care
- The cancer cell and model systems
- Tumour-specific research

**Chernobyl: Fact from fiction – the benefit of 25 years hindsight and integrated research**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15.45 – 16.00 | Introduction  
Geraldine Thomas, Chernobyl Tissue Bank & Imperial College, London, UK |
| 16.00 – 16.25 | Clinical outcomes in radiation-induced thyroid cancer  
Michael Tuttle, Memorial Sloan-Kettering Cancer Center, New York, USA |
| 16.25 – 16.50 | The epidemiology of radiation-induced thyroid disease  
Elisabeth Cardis, The Centre for Research in Environmental Epidemiology, Barcelona, Spain |
| 16.50 – 17.15 | Managing environmental monitoring programmes following a major nuclear accident  
Paul Leonard, University of Exeter, UK |

**Improving patient outcomes in lymphoma**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15.45 – 16.00 | Introduction  
John Radford, University of Manchester, UK |
| 16.00 – 16.25 | Promising new drugs in lymphoma – opportunities for changing practice  
Bruce D. Cheson, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, USA |
| 16.25 – 16.50 | Reduced intensity allogeneic transplantation for relapsed lymphoma  
Stephen Mackinnon, University College Hospital, London, UK |
| 16.50 – 17.15 | Late treatment effects in patients with lymphoma – their impact on the duration and quality of survival  
Flora E. van Leeuwen, The Netherlands Cancer Institute, Amsterdam, The Netherlands |

**Liver and colorectal cancer**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15.45 – 16.00 | Introduction  
Tim Maughan, Gray Institute for Radiation Oncology & Biology, Oxford, UK |
| 16.00 – 16.25 | The tumour vasculature in metastatic CRC: Beyond the obvious  
Lee Ellis, MD Anderson Cancer Center, Texas, USA |
16.25 – 16.50 Exploiting knowledge of DNA damage repair to improve treatment for patients with colorectal cancer
Ricky Sharma, University of Oxford, UK

16.50 – 17.15 Molecular selection of therapy in colorectal cancer: Clinical trials
Richard Wilson, Queen’s University Belfast, UK

Paediatric oncology: Survivorship from childhood cancer

Hall 1B Hosted by Adam Glaser, St. James’s Hospital, Leeds, UK

15.45 – 16.00 Introduction
Adam Glaser1 and Ken Calman2, 1St. James’s Hospital, Leeds, UK; 2University of Glasgow, UK

16.00 – 16.25 Detection of the late effects of cancer: Surveillance and the role of genetic risk factors
Kevin Oeffinger, Memorial Sloan-Kettering Cancer Center, New York, USA

16.25 – 16.50 Cardiac toxicity in survivors of childhood cancer
Leontien C. Kremer, University of Amsterdam, The Netherlands

16.50 – 17.15 Screening, preventative and chronic disease care in cancer survivors
Nada Khan, University of Oxford, UK

Phosphoinositol signalling and cancer

Room 11 Hosted by Bart Vanhaesebroeck, Barts Cancer Institute, London, UK

15.45 – 16.00 Introduction
Bart Vanhaesebroeck, Barts Cancer Institute, London, UK

16.00 – 16.25 CAL-101 (GS-1101)-based targeted therapy in Mantle Cell Lymphoma (MCL), Indolent Non-Hodgkin Lymphoma (iNHL) and Chronic Lymphocytic Leukemia (CLL)
Thomas Jahn, Gilead Sciences, Inc., Seattle, USA

16.25 – 16.50 Class III phosphatidylinositol 3-kinase as tumour suppressor
Harald Stenmark, The Norwegian Radium Hospital, Oslo, Norway

16.50 – 17.15 Direct and indirect actions of PI 3-kinase in cancer
Bart Vanhaesebroeck, Barts Cancer Institute, London, UK

Prognostication in advanced cancer: How and why?

Hall 1C Hosted by John Ellershaw, University of Liverpool & Marie Curie Palliative Care Institute Liverpool, UK

15.45 – 16.00 Introduction
John Ellershaw, University of Liverpool & Marie Curie Palliative Care Institute Liverpool, UK

16.00 – 16.25 The use of prognostic tools in palliative care
Paddy Stone, St George’s University, London, UK

16.25 – 16.50 Dialogues to improve end-of-life care: Prognostication and advance care planning
Jane Seymour, University of Nottingham, UK

16.50 – 17.15 Diagnosing dying: Findings of a European Collaborative Study OPCARE9
John Ellershaw, University of Liverpool & Marie Curie Palliative Care Institute Liverpool, UK
## The first century of human tumour virology

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.45</td>
<td>Introduction</td>
</tr>
<tr>
<td>15.50</td>
<td>Hosted by Chris Boshoff, University College London Cancer Institute, London, UK</td>
</tr>
<tr>
<td>16.00</td>
<td>Introduction</td>
</tr>
<tr>
<td></td>
<td>Chris Boshoff, University College London Cancer Institute, London, UK</td>
</tr>
<tr>
<td>16.00</td>
<td>Lessons from the small DNA tumour viruses</td>
</tr>
<tr>
<td>16.25</td>
<td>Daniel DiMaio, Yale University School of Medicine, New Haven, USA</td>
</tr>
<tr>
<td>16.25</td>
<td>Mechanisms of human papillomavirus-induced malignancy</td>
</tr>
<tr>
<td>16.50</td>
<td>Lawrence Banks, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy</td>
</tr>
<tr>
<td>16.50</td>
<td>Mechanisms of Epstein-Barr virus lymphomagenesis</td>
</tr>
<tr>
<td></td>
<td>Martin Rowe, University of Birmingham, UK</td>
</tr>
</tbody>
</table>

## Translational control and cancer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.45</td>
<td>Introduction</td>
</tr>
<tr>
<td>15.50</td>
<td>Hosted by Robert White, The Beatson Institute for Cancer Research, Glasgow, UK</td>
</tr>
<tr>
<td>16.00</td>
<td>Introduction</td>
</tr>
<tr>
<td></td>
<td>Robert White, The Beatson Institute for Cancer Research, Glasgow, UK</td>
</tr>
<tr>
<td>16.00</td>
<td>Translating the PI3K/mTOR pathway and translational control to radiation therapy</td>
</tr>
<tr>
<td>16.25</td>
<td>Robert Schneider, New York University Langone Medical Center, USA</td>
</tr>
<tr>
<td>16.25</td>
<td>Translational control of pancreatic carcinogenesis</td>
</tr>
<tr>
<td>16.50</td>
<td>Stéphane Pyronnet, French National Institute of Health and Medical Research (Inserm), Toulouse, France</td>
</tr>
<tr>
<td>16.50</td>
<td>Deregulation of gene expression at the level of translation in diffuse large B-cell lymphoma</td>
</tr>
<tr>
<td></td>
<td>Anne Willis, Medical Research Council Toxicology Unit, Leicester, UK</td>
</tr>
</tbody>
</table>
Proffered paper sessions in detail **TUESDAY**

**KEY TO THEMES:**
- Diagnosis and therapy
- Epidemiology and prevention
- Information, patients and the public
- Survivorship and end-of-life care
- The cancer cell and model systems
- Tumour-specific research

**Cancer cell and model systems II**

Room 3B
Hosted by Caroline Dive, Paterson Institute for Cancer Research, Manchester, UK

14:00 - 14:15  **BACR AstraZeneca Young Scientist Frank Rose Award:** Role of an oncogenic enzyme sphingosine kinase 1 in the development of proinflammatory tumour microenvironment and prostate cancer chemoresistance
Dimitry Psheztskiy, Imperial College, London, UK

14:15 – 14:30  **ACP McElwain Prize:** Laboratory and clinical studies of the dual EGFR/HER2 tyrosine kinase inhibitor, lapatinib, in breast cancer
Alexandra Leary, The Royal Marsden NHS Foundation Trust, Sutton, UK

14:30 – 14:40  CtBPs proteins: Transcriptional sensors of the Warburg effect and potential targets for tumour therapy
Jeremy Blaydes, University of Southampton, UK

14:40 – 14:50  Role of autocrine TNF in pancreatic tumour progression
Maud Bossard, Queen Mary University of London, UK

14:50 – 15:00  Small-molecule inhibitors of metabolic flux as potential antitumour agents
Jonathan Williams, University of Oxford, UK

15:00 - 15:10  Elevated stromal Foxp3+ regulatory T cells combined with low density CD8+ cytotoxic T cells are associated with colorectal metastatic tumour progression
Helen Angell, University of Nottingham, UK

15:00 - 15:10  mTORC1 is an important downstream mediator of Wnt signalling activation in the intestinal epithelium
William Faller, Beatson Institute, Glasgow, UK

15:20 - 15:30  Discussion

**Gastrointestinal cancer**

Room 3A
Hosted by Philip Quirke, University of Leeds, UK

14:00 - 14:15  **PICCOLO** – a large multicentre trial with molecular stratification in chemoresistant advanced colorectal cancer: Evaluation of panitumumab in combination with irinotecan
Matt Seymour, Leeds Institute of Molecular Medicine, University of Leeds, UK

14:15 - 14:30  Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the two-arm phase II randomised MRC COIN-B trial
Harpreet Wasan, Hammersmith Hospital, London, UK

---

80  www.ncr.org.uk/ncriconference
**Clinical trials**

**Hosted by Johann de Bono, The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research, Sutton, UK**

**Hall 1A**

**14:00 - 14:15**
British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine (1250mg/m²) combined with cisplatin 50mg/m² (GC50) versus cisplatin 80mg/m² (GC80) versus carboplatin AUC 6 (GCb6) in advanced NSCLC  
David Ferry, New Cross Hospital, Wolverhampton, UK

**14:15 - 14:30**
Adjuvant zoledronic acid in stage II/III breast cancer. Discordant effects according to menopausal status in the AZURE trial (BIG 01/04)  
Robert Coleman, University of Sheffield, UK

**14:30 - 14:45**
Periampullary cancer ESPAC-3(v2) trial: A randomised controlled phase III Trial of adjuvant chemotherapy versus observation in patients with periampullary adenocarcinomas of the head of the pancreas  
John Neoptolemos, University of Liverpool, UK

**14:45 - 15:00**
A phase I dose escalation study of oral MK-2206 (Allosteric AKT Inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK Inhibitor) in patients with advanced or metastatic solid tumours  
Johann de Bono, The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research, Sutton, UK

**15:00 - 15:15**
A randomised phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN53643604)  
Robert A. Huddart, The Institute of Cancer Research, Sutton, UK

**15:15 - 15:30**
Discussion
## Breakfast Educational Workshop

08.10 – 08.55  **BACR educational workshop**  
Unlocking the development and progression of childhood cancer  

**Hosted by Sue Burchill**, Leeds Institute of Molecular Medicine, University of Leeds, UK  

For many children with cancer, survival rates are dismal. As with most cancers, the biggest challenge for patient cure is usually the development of metastatic drug-resistant disease. Increased understanding of the factors and pathways regulating the development and progression of this disease may identify and prioritise target(s) and pathway(s) for the development of more effective treatment.

In this workshop the application of human-induced pluripotent stem (iPS) cell technology to investigate the earliest events in tumour initiation, progression and development of childhood cancers will be reviewed. The session will describe iPS cells, an exciting source of cells with limitless self-renewal capacity and the potential to differentiate into multiple cell types, and how reprogramming childhood cancer cells to cancer-derived iPS cells may provide a model to study the primary events involved in the initiation and progression of these cancers. Such cells might provide a sustainable resource for research in rare cancers, where the amount of primary tumour is usually small and so can limit biological studies. The potential value and limitations of studying childhood cancer-derived iPS cells will be discussed.

## Commercial Workshops

13.00 – 14.00  **Headlines of international conferences in 2011 – a Roche-sponsored symposium**  

**Hosted by Roche**  
*Lunch will be provided from 12.40*  

What have been the latest developments in cancer research and treatment? Taking the data from past congresses, the Roche-sponsored symposium will present an independent view of the headline data from this year’s key congresses. Roche welcomes all NCRI delegates to attend this Roche-sponsored symposium and hear from a clinician’s perspective how the highlights of congresses such as the American Society of Clinical Oncology Annual Meeting have impacted patient care in the UK.

13.00 – 14.00  **New frontiers in cancer: Sequencing the complete cancer genome**  

**Hosted by Complete Genomics, Inc.**  
*Lunch will be provided from 12.40*  

As the cost of sequencing human genomes continues to decline, it is becoming feasible to conduct research projects that involve the sequencing of thousands of genomes. Such studies offer the promise of elucidating the genetic basis of a wide spectrum of simple and complex diseases including cancer. Technology advances, including high-throughput sequencing equipment, advances in high-speed computing, improved bioinformatics tools, and cloud-based data storage, delivery and sequence...
analysis, will continue to drive down the cost and improve the quality of complete genome sequencing and enable many more such projects over the next few years. Clinical-quality genome sequencing offers a dramatic new approach to detecting, diagnosing, and treating cancer.

Speakers:
Stephen E. Lincoln, Complete Genomics
Amy Sherborne, The Institute of Cancer Research, UK

Afternoon Workshops

14.00 – 15.30 Improving access to samples for research – the role of engagement
Hall 1B Hosted by Jane Hair¹ and Margaret Wilcox², 'NHS Glasgow and Greater Clyde Bio-repository, UK;' Breast Cancer Campaign Tissue Bank & Independent Cancer Patients’ Voice, UK
The need for greater numbers of high quality human samples for cancer research has driven the growth of cancer biobanks in the UK. Much of the focus of individual biobanks has been on securing funding and negotiating the ethical and regulatory requirements, however stakeholder engagement is a vital aspect of successful biobanking and one that has received much less attention. This workshop will provide an opportunity for interactive discussion on the benefits of engaging with three major stakeholder groups: the potential donors of the samples, the healthcare team who often identify donors, and the researchers who will ultimately use the samples in their studies.

The particular needs of each group will be reviewed and current examples of engagement by Biobanks in the UK will be presented and discussed. The CCB aims to develop a guide to best practice from the discussion and therefore welcomes attendees from each of the groups highlighted as well as the biobanking community.

Speakers:
Engaging and involving donors from the start
Adrienne Morgan and Louise Jones, Breast Cancer Campaign Tissue Bank, UK
Successful embedding of tissue donation/consent as part of the patient journey
Jane Hair and Roma Armstrong, NHS Glasgow and Greater Clyde Bio-repository, UK
Providing researchers with optimal access to samples
Malcolm Mason, Cardiff University & Velindre Hospital, UK

14.00 – 15.30 Careers in industry
Room 4 Hosted by Altaf Moledina, on behalf of the NCRI Industry Consultation Group
Following the highly successful Post-Doc Careers session held at the Conference in 2009, we are pleased to announce that the NCRI Industry Consultation Group will again host an interactive careers workshop at this year’s Conference.

The session will feature a variety of commercial career paths for post-docs including:
1. Medical and Scientific Affairs
2. Clinical Research
3. Drug Discovery
4. Sales and Marketing
5. Outcome Research / Evidence-based Medicine
6. Translational / Diagnostic Technologies
7. Medical Communications
8. Association of British Pharmaceutical Industry (ABPI) Careers

Representatives of several companies (Roche, AstraZeneca, Pfizer, Illumina, GSK, Bristol-Myers Squibb, among others) will be at the stations above to explain their roles and discuss career paths in these fields. The session will be an informal discussion and all questions are welcome.

14.00 – 15.30  
**Spotlight on survivorship: Developing evidence-based support services**
- Hosted by Owen Sharp, Chief Executive, The Prostate Cancer Charity

The National Cancer Survivorship Initiative (NCSI) vision document of 2010 identified five areas in which progress is needed to provide better care and support for people living with and beyond cancer:

- Greater focus on recovery, health and wellbeing after cancer treatment
- A shift towards assessment, information provision and personalised care planning
- Support for self-management
- A move from a single model of clinical follow-up
- More emphasis on measuring experience and outcomes for people surviving cancer

Using prostate cancer as an example, this workshop will highlight how research in cancer survivorship can help us move towards these goals.

Vivien Pipe, awareness volunteer for The Prostate Cancer Charity, will talk about the prostate cancer journey and present evidence on where the needs of people living with the disease are not currently met. Delegates will then hear about a new service being developed by the charity in partnership with academic researchers at King’s College London, to help men manage cancer-related fatigue. Finally, there will be an interactive session where participants will have an opportunity to identify and discuss the key questions in survivorship, think about their own priorities, and suggest ways in which barriers to survivorship research and the translation of research findings into practice can be overcome.

The summarised findings of this workshop will be fed back to participants after the conference.

**Speakers:**
- Vivien Pipe, The Prostate Cancer Charity Awareness volunteer
- Ben Langston, Research and Development Associate, The Prostate Cancer Charity & Kings College London, UK

14.00 – 15.30  
**Radiotherapy: The quiet revolution**
- Hosted by Tim Maughan, Gray Institute for Radiation Oncology & Biology, Oxford, UK

All are aware that targeted therapy has revolutionised our approach to systemic cancer therapy. What is much less widely understood is that radiotherapy has undergone a quiet revolution enabling exquisite physical targeting of the cancer using new techniques which are rapidly coming into clinical practice. This session will bring together policy advisors, patients, clinicians and researchers to update attendees on the changes that have occurred, what is being done to implement in the NHS and how we
can build on this basis in the future. Radiotherapy research is a priority for the NCRI. The application of cutting edge science to this field carries the opportunity of very significant improvements in outcome for cancer patients.

14.00 – 15.30  **Head and neck cancer research workshop**

**Hall 1C**  
Hosted by Catharine West\(^1\) and Richard Shaw\(^2\), \(^1\)University of Manchester, UK; \(^2\)University of Liverpool, UK

This is the first UK forum to showcase current head and neck cancer translational and basic science research.

It will be an informal and collegiate event with open exchange of ideas, and offers potential opportunities to new researchers and for those already established.

Target audience: Translational & basic scientists, Head and Neck clinicians, research trainees.
Programme at a glance WEDNESDAY

Plenary Lecture
Chaired by Tim Maughan, Gray Institute for Radiation Oncology & Biology, Oxford, UK
09.00 – 09.40 Stratified medicine in colorectal cancer: Current state and challenges ahead
Hall 1 Sabine Tejpar, Digestive Oncology and Center for Human Genetics, University Hospital Leuven, Belgium

Refreshment Break
09.40 – 10.10 Refreshment break
Registration area & Galleria

Parallel Sessions
KEY TO THEMES:
- Diagnosis and therapy
- Epidemiology and prevention
- Information, patients and the public
- Survivorship and end-of-life care
- The cancer cell and model systems
- Tumour-specific research

10.10 – 11.40 Biomarker validation and adaptive clinical trial design
Hall 1A Hosted by Caroline Dive, Paterson Institute for Cancer Research, Manchester, UK

10.10 – 11.40 Cancer awareness and early diagnosis: International perspectives
Room 4 Hosted by Amanda Ramirez¹ and Jane Wardle², ¹King’s College London, UK; ²University College London, UK

10.10 – 11.40 Clinical and translational approaches to radiotherapy
Room 3A Hosted by Gillies McKenna, Gray Institute for Radiation Oncology & Biology, Oxford, UK

10.10 – 11.40 Genomics analysis of intratumour heterogeneity and drug resistance mechanisms in cancer medicine
Room 3B Hosted by Charles Swanton, Cancer Research UK London Research Institute, UK

10.10 – 11.40 Genetic predisposition to cancers – future implications for selective screening, surveillance and management
Hall 1B Hosted by Rosalind Eeles, The Institute of Cancer Research, Sutton, UK

10.10 – 11.40 Genomic instability and cancer: Lessons from analysis of Bloom’s syndrome
Room 11 Hosted by Ian Hickson, University of Copenhagen, Denmark
10.10 – 11.40  **Lung cancer treatment: We have lift-off!**  
Room 12  Hosted by Marianne Nicolson, Aberdeen University Hospitals, NHS Grampian, UK  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.10 – 11.40</td>
<td>Lung cancer treatment: We have lift-off!</td>
<td>Room 12</td>
</tr>
<tr>
<td></td>
<td>Hosted by Marianne Nicolson, Aberdeen University Hospitals, NHS Grampian, UK</td>
<td></td>
</tr>
<tr>
<td>11.40 – 11.55</td>
<td>Refreshment break</td>
<td>Registration area &amp; Galleria</td>
</tr>
<tr>
<td>11.55 – 12.35</td>
<td>Plenary Lecture</td>
<td>Hall 1</td>
</tr>
<tr>
<td></td>
<td>Chaired by Nic Jones, Manchester Cancer Research Centre &amp; Cancer Research UK</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Evolution of the cancer genome</td>
<td>Michael R. Stratton, Wellcome Trust Sanger Institute, Cambridge, UK</td>
</tr>
<tr>
<td>12.35 – 12.45</td>
<td>Closing comments</td>
<td>Hall 1</td>
</tr>
<tr>
<td></td>
<td>Closing remarks</td>
<td>Dame Janet Husband, Chair of the National Cancer Research Institute, UK</td>
</tr>
<tr>
<td>12.45 – 13.15</td>
<td>Lunch</td>
<td>Registration area</td>
</tr>
<tr>
<td>14.00 – 16.45</td>
<td>Satellite symposium</td>
<td>Room 3B</td>
</tr>
<tr>
<td></td>
<td>The Chernobyl Tissue Bank research symposium: A model for integrated biology research in cancer – radiation-induced thyroid cancer</td>
<td></td>
</tr>
</tbody>
</table>
Parallel sessions in detail WEDNESDAY

KEY TO THEMES:
- Diagnosis and therapy
- Epidemiology and prevention
- Information, patients and the public
- Survivorship and end-of-life care
- The cancer cell and model systems
- Tumour-specific research

Biomarker validation and adaptive clinical trial design

Hall 1A Hosted by Caroline Dive, Paterson Institute for Cancer Research, Manchester, UK
10.10 – 10.30 Introduction Caroline Dive, Paterson Institute for Cancer Research, Manchester, UK
10.30 – 10.50 Fit-for-purpose biomarker validation Howard Scher, Memorial Sloan-Kettering Cancer Center, New York, USA
10.50 – 11.20 Biomarkers in early drug development Josep Tabernero, Vall d’Hebron University Hospital, Barcelona, Spain
11.20 – 11.40 Adaptive trial design that incorporates biomarkers Lucinda Billingham, MRC Midland Hub for Trials Methodology Research & Cancer Research UK Clinical Trials Unit, University of Birmingham, UK

Cancer awareness and early diagnosis: International perspectives

Room 4 Hosted by Amanda Ramirez¹ and Jane Wardle², ¹King’s College London, UK; ²University College London, UK
10.10 – 10.30 Introduction Amanda Ramirez, King’s College London, UK
10.30 – 10.50 International differences in cancer awareness and beliefs: The International Cancer Benchmarking Partnership Lindsay Forbes, King’s College London, UK
10.50 – 11.20 Cancer awareness and early diagnosis in Denmark: A rewarding intervention? Peter Vedsted, Aarhus University, Denmark
11.20 – 11.40 Public attitudes and awareness of cancer risks and early detection: A Canadian perspective Heather Bryant, Canadian Partnership Against Cancer, Toronto, Canada & University of Calgary, Canada

Clinical and translational approaches to radiotherapy

Room 3A Hosted by Gillies McKenna, Gray Institute for Radiation Oncology & Biology, Oxford, UK
10.10 – 10.30 Introduction Gillies McKenna, Gray Institute for Radiation Oncology & Biology, Oxford, UK
10.30 – 10.50 Strategies for radiosensitisation targeting the tumour microenvironment Ruth Muschel, Gray Institute for Radiation Oncology & Biology, Oxford, UK
10.50 – 11.20 The role of functional imaging in developing strategies towards a patient-tailored approach in prostate cancer
Karin Haustermans, University Hospital, Leuven, Belgium

11.20 – 11.40 Patient-specific mathematical radiation oncology: Integrating clinical imaging and modelling to improve outcomes
Kristin Swanson, University of Washington, Seattle, USA

Genomics analysis of intratumour heterogeneity and drug resistance mechanisms in cancer medicine

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Host/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.10 – 10.30</td>
<td>Introduction</td>
<td>Charles Swanton, Cancer Research UK London Research Institute, UK</td>
</tr>
<tr>
<td>10.30 – 10.50</td>
<td>Breast cancer intratumour heterogeneity: A challenge for personalised medicine</td>
<td>James Hicks, Cold Spring Harbor Laboratory, New York, USA</td>
</tr>
<tr>
<td>10.50 – 11.20</td>
<td>Dissecting mechanisms of cancer drug resistance through functional genetics</td>
<td>Rene Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>11.20 – 11.40</td>
<td>Intratumoural heterogeneity and the evolution of drug resistance in high-grade serous ovarian cancer</td>
<td>James Brenton, Cancer Research UK Cambridge Research Institute, UK &amp; University of Cambridge, UK</td>
</tr>
</tbody>
</table>

Genetic predisposition to cancers – future implications for selective screening, surveillance and management

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Host/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.10 – 10.30</td>
<td>Introduction</td>
<td>Rosalind Eeles, The Institute of Cancer Research, Sutton, UK</td>
</tr>
<tr>
<td>10.30 – 10.50</td>
<td>Predicting cancer risk using genetic variation</td>
<td>Douglas Easton, University of Cambridge, UK</td>
</tr>
<tr>
<td>10.50 – 11.20</td>
<td>Genetic predisposition to cancer – implications for selective screening</td>
<td>Harry de Koning, Erasmus MC &amp; Johns Hopkins Bloomberg School of Public Health, Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>11.20 – 11.40</td>
<td>Using germline susceptibility testing to inform the treatment of newly diagnosed cancer patients</td>
<td>Mark Robson, Memorial Sloan-Kettering Cancer Center, New York, USA</td>
</tr>
</tbody>
</table>

Genomic instability and cancer: Lessons from analysis of Bloom’s syndrome

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Host/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.10 – 10.30</td>
<td>Introduction</td>
<td>Ian Hickson, University of Copenhagen, Denmark</td>
</tr>
<tr>
<td>10.30 – 10.50</td>
<td>Regulation of recombination-mediated DSB repair and its importance for genome stability</td>
<td>Stephen West, Cancer Research UK London Research Institute, UK</td>
</tr>
<tr>
<td>10.50 – 11.20</td>
<td>The human mismatch repair interactome</td>
<td>Josef Jiricny, Institute of Molecular Cancer Research, Zurich, Switzerland</td>
</tr>
<tr>
<td>11.20 – 11.40</td>
<td>The BRCA1-BRCA2 pathway of homologous recombination</td>
<td>Simon Powell, Memorial Sloan-Kettering Cancer Center, New York, USA</td>
</tr>
</tbody>
</table>

122  www.ncri.org.uk/ncriconference
Lung cancer treatment: We have lift-off!

Room 12 Hosted by Marianne Nicolson, Aberdeen University Hospitals, NHS Grampian, UK

10.10 – 10.30 Introduction
Marianne Nicolson, Aberdeen University Hospitals, NHS Grampian, UK

10.30 – 10.50 Population-based data on lung cancer from the UK: The National Audit and beyond
Michael Peake, Glenfield Hospital, Leicester, UK; National Lung Cancer Audit, London, UK & National Cancer Intelligence Network, London, UK

10.50 – 11.20 Modern radiotherapy techniques and progress in non-small cell lung cancer
Suresh Senan, VU University Medical Center, Amsterdam, The Netherlands

11.20 – 11.40 Title to be confirmed
Luis Paz-Ares, Hospital Universitario Virgen del Rocio, Seville, Spain